MedImmune Announces Agreement with Progenics Pharmaceuticals to Develop Therapies Against Serious Bacterial Infections

   MedImmune Announces Agreement with Progenics Pharmaceuticals to Develop
                Therapies Against Serious Bacterial Infections

PR Newswire

GAITHERSBURG, Md., Dec. 17, 2012

GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ --MedImmune, the global
biologics arm of AstraZeneca, announced that it has signed an in-licensing
agreement with Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) for Progenics'
Clostridium difficile late-stage preclinical program. The agreement was led
by MedImmune's Infectious Diseases & Vaccines Innovative Medicines (iMed)
Unit.

Clostridium difficile infections are the leading cause of hospital-acquired
bacterial infections in the U.S. and are associated with more than 20,000
deaths and more than $1 billion in healthcare costs annually. The disease
causes severe diarrhea in patients and  significantly lengthens the time
patients stay in the hospital, leading to poorer outcomes. MedImmune's program
for this property will assess the potential efficacy and safety of treatment
of the infection with investigational monoclonal antibodies targeting toxins
that mediate the disease.

Financial details of the agreement were not disclosed.

"This deal exemplifies MedImmune's commitment to researching and developing
new and better treatments for addressing serious bacterial infections," said
Steve Projan, Senior Vice President and Infectious Disease iMed Head at
MedImmune. "The Clostridium difficile program fits strategically within our
infectious disease portfolio and adds to our existing programs that aim to
prevent and treat serious bacterial infections, particularly among high-risk
patients."

Preliminary research from the program suggests that the antibodies being
developed are highly potent against most of the strains found in the U.S. and
Asia, and are potent against hypervirulent strains, which produce higher
amounts of toxins and are a main contributor to the growing rate of the
disease.

"The burden C. difficile infection puts on patients' lives and our healthcare
systems is a substantial one," said Mark R. Baker, Progenics' Chief Executive
Officer. "As a company with a strong heritage in medical research, Progenics
is pleased to have this product candidate in MedImmune's hands where it has
the potential to improve human health."

About C. Difficile

C. difficile is an anaerobic bacterium that is mediated by toxins, which can
damage the lining of the gut causing severe symptoms such as diarrhea and
cramping, and prevent normal, beneficial bacteria (flora) in the gut from
growing back. An estimated 500,000 cases are diagnosed in the U.S. annually,
resulting in more than20,000 deaths yearly.

The infection most often occurs in people who have been hospitalized, although
up to 28 percent of cases are community-acquired through contaminated soil,
water, pets, cattle, and foods. Among people hospitalized, the incidence rate
of the disease increases the longer a person stays in the hospital – from
about 13 percent after a two-week stay to nearly 50 percent after four weeks.
The infection has an estimated 10 to 60 percent chance of recurring, depending
on the patient's risk factors such as age, bacterial strain, and re-growth of
normal, healthy bacteria in the gut.

Leadership in Infectious Diseases

MedImmune's historical roots are in infectious disease. In 1998, it was the
first company to launch a monoclonal antibody in the U.S. targeting an
infectious disease (respiratory syncytial virus or RSV).

The company also is recognized as a leader in vaccine development, introducing
the first influenza vaccine innovation in more than 60 years – intranasal
delivery in 2003. MedImmune introduced another first earlier this year, the
world's first four-strain flu vaccine, approved by the FDA in February and
available in the U.S. in 2013.

MedImmune continues to explore how biologics can address the most
hard-to-treat infectious diseases and help fulfill unmet needs among patients.
Research is ongoing in such diverse areas as antibacterials, respiratory
viruses and novel vaccines.

About MedImmune

MedImmune, the global biologics arm for AstraZeneca PLC, has approximately
3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For
more information, visit MedImmune's website atwww.medimmune.com.

About Progenics

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical
company dedicated to developing innovative medicines to treat disease, with a
focus on cancer and related conditions. Progenics' pipeline candidates
include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2
testing for treatment of prostate cancer, and preclinical stage novel
phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.
Progenics has exclusively licensed development and commercialization rights
for its opioid-induced constipation drug, Relistor, to Salix Pharmaceuticals,
Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co.,
Ltd. holds an exclusive license for the subcutaneous formulation. Relistor
(methylnaltrexone bromide) subcutaneous injection is a first-in-class
treatment for opioid-induced constipation approved in more than 50 countries
for patients with advanced illness.



SOURCE MedImmune

Website: http://www.medimmune.com
Contact: Michael O'Brien, MedImmune, +1-301-398-2133, obrienm@medimmune.com;
or Amy Martini, Progenics, +1-914-789-2816, amartini@progenics.com
 
Press spacebar to pause and continue. Press esc to stop.